PMGC Expands Space Biotech Push with Orbit2Orbit Collaboration — PMGC Holdings Inc.

Event summary

PMGC Holdings has signed a non-binding term sheet with Orbit2Orbit for a multi-part strategic relationship, including a spaceflight study of its muscle-loss therapeutics EL-22 and EL-32.
The Mice2Space study will evaluate EL-22 and EL-32 in mice for muscle retention in microgravity, with NorthStrive Bio leading the scientific study and Orbit2Orbit handling the spaceflight platform.
A&B Aerospace will serve as Orbit2Orbit’s preferred U.S.-based manufacturing partner for the Mice2Space program and other future hardware.
PMGC plans to invest CAD $200,000 in Orbit2Orbit as part of its private placement financing and proposed listing on the Canadian Securities Exchange.

The big picture

PMGC’s collaboration with Orbit2Orbit represents a strategic pivot into the burgeoning space biotech sector, combining its biopharmaceutical assets with Orbit2Orbit’s spaceflight capabilities. This move aligns with the broader trend of commercializing space for scientific research, particularly in areas like muscle atrophy, which has significant implications for both space travel and Earth-based medical applications. The proposed investment in Orbit2Orbit further underscores PMGC’s commitment to diversifying its portfolio within the rapidly expanding commercial space economy.

What we're watching

Execution Risk: Whether PMGC can successfully navigate the complexities of space-based biotech research and manufacturing partnerships.
Strategic Alignment: How the integration of NorthStrive Bio’s therapeutics with Orbit2Orbit’s spaceflight platform will impact PMGC’s growth in the commercial space economy.
Market Expansion: The pace at which PMGC can leverage this collaboration to expand its footprint in the growing commercial space industry.